Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. The company is headquartered in Seattle, Washington and currently employs 194 full-time employees. The company went IPO on 2021-02-04. The company is engaged in developing ex vivo and in vivo cell engineering platforms to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including type 1 diabetes (T1D), B cell mediated autoimmune diseases, and oncology. The company develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline includes SC451, SC291, SC262, SG299 and UP421. SC451 is a pluripotent stem cell (PSC)-derived hypoimmune pancreatic islet cell product candidate for the treatment of diabetes, with an initial focus on T1D. The firm is developing SC262, its hypoimmune-modified CD22-directed allogeneic CAR T program, initially as a potential treatment for patients with relapsed and/or refractory B cell malignancies who have received prior CD19-directed CAR T therapy in non-Hodgkin's lymphoma.
Follow-Up Questions
Who is the CEO of Sana Biotechnology Inc?
Mr. Steven Harr is the President of Sana Biotechnology Inc, joining the firm since 2018.
What is the price performance of SANA stock?
The current price of SANA is $3.32, it has increased 0.94% in the last trading day.
What are the primary business themes or industries for Sana Biotechnology Inc?
Sana Biotechnology Inc belongs to Biotechnology industry and the sector is Health Care
What is Sana Biotechnology Inc market cap?
Sana Biotechnology Inc's current market cap is $818.1M
Is Sana Biotechnology Inc a buy, sell, or hold?
According to wall street analysts, 8 analysts have made analyst ratings for Sana Biotechnology Inc, including 5 strong buy, 7 buy, 2 hold, 0 sell, and 5 strong sell
